marketcaparena
Search

    KAPA

    Kairos Pharma, LTD.

    Company overview

    Market capitalization
    —
    Employees
    1
    Latest publication
    2026-09-29
    About Kairos Pharma, LTD.

    Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Total Revenue0USD0USD0USD0USD0USD0USD0USD0USD
    Cost Of Revenue40,000USD-120,000USD40,000USD40,000USD40,000USD—40,000USD40,000USD
    Gross Profit-40,000USD120,000USD-40,000USD-40,000USD-40,000USD—-40,000USD-40,000USD
    Research Development684,000USD538,000USD608,000USD496,000USD493,000USD172,000USD14,000USD63,000USD
    Selling General Administrative1,006,000USD837,000USD787,000USD920,000USD733,000USD1,234,000USD329,000USD119,000USD
    Total Operating Expenses1,577,000USD1,683,000USD1,435,000USD1,456,000USD1,266,000USD1,446,000USD343,000USD182,000USD
    Operating Income-1,617,000USD-1,563,000USD-1,435,000USD-1,456,000USD-1,266,000USD-1,446,000USD-383,000USD-222,000USD
    Interest Income36,000USD50,000USD37,000USD34,000USD4,000USD—0USD0USD
    Net Interest Income36,000USD50,000USD37,000USD34,000USD4,000USD-133,000USD-664,000USD-31,000USD
    Income Before Tax-1,654,000USD-1,365,000USD-1,398,000USD-1,422,000USD-1,262,000USD-980,000USD-1,046,999USD-253,000USD
    Net Income-1,654,000USD-1,365,000USD-1,398,000USD-1,422,000USD-1,262,000USD-980,000USD-1,046,999USD-253,000USD
    Net Income From Continuing Ops-1,654,000USD-1,365,000USD-1,398,000USD-1,422,000USD-1,262,000USD-980,000USD-1,047,000USD-253,000USD
    Ebit-1,617,000USD-1,365,000USD-1,398,000USD-1,422,000USD-1,262,000USD—-383,000USD-222,000USD
    Ebitda-1,577,000USD-1,325,000USD-1,358,000USD-1,382,000USD-1,222,000USD—-343,000USD-182,000USD
    Depreciation And Amortization40,000USD40,000USD40,000USD40,000USD40,000USD—40,000USD40,000USD
    Reconciled Depreciation40,000USD40,000USD40,000USD40,000USD40,000USD40,000USD40,000USD40,000USD
    Total Other Income Expense Net-37,000USD198,000USD37,000USD34,000USD4,000USD—-663,999USD-31,000USD
    Interest Expense—0USD0USD0USD133,000USD0USD664,000USD31,000USD
    Selling And Marketing Expenses————165,000USD———
    Income Tax Expense————-2,603,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USD
    Total Revenue0USD0USD0USD0USD0USD0USD
    Research Development2,135,000USD414,000USD82,000USD87,000USD183,000USD20,000USD
    Selling General Administrative3,437,000USD1,929,000USD1,472,000USD324,000USD1,662,000USD1,026,000USD
    Total Operating Expenses5,572,000USD2,183,000USD1,554,000USD411,000USD1,845,000USD1,045,941USD
    Operating Income-5,572,000USD-2,343,000USD-1,714,000USD-571,000USD-1,943,000USD-1,045,941USD
    Interest Income125,000USD0USD————
    Interest Expense0USD859,000USD98,000USD479,000USD202,000USD5,411USD
    Net Interest Income125,000USD-859,000USD-98,000USD-479,000USD-202,000USD-5,411USD
    Income Before Tax-5,447,000USD-2,603,000USD-1,812,000USD-1,050,000USD-2,145,000USD-1,051,353USD
    Net Income-5,447,000USD-2,603,000USD-1,812,000USD-1,050,000USD-2,145,000USD-1,051,353USD
    Net Income From Continuing Ops-5,447,000USD-2,603,000USD-1,812,000USD-1,050,000USD-2,145,000USD-1,051,411USD
    Ebit-5,447,000USD-1,744,000USD-1,714,000USD-571,000USD-1,943,000USD-1,045,942USD
    Ebitda-5,287,000USD-1,584,000USD-1,554,000USD-411,000USD-1,845,000USD-1,045,942USD
    Depreciation And Amortization160,000USD160,000USD160,000USD160,000USD98,000USD-58USD
    Reconciled Depreciation160,000USD160,000USD160,000USD160,000USD98,000USD0USD
    Total Other Income Expense Net125,000USD-260,000USD-98,000USD-479,000USD-202,000USD-5,411USD
    Cost Of Revenue—160,000USD160,000USD160,000USD98,000USD—
    Gross Profit—-160,000USD-160,000USD-160,000USD-98,000USD—
    Income Tax Expense—-2,603,000USD————
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets4,456,000USD5,744,000USD6,540,000USD8,066,000USD6,673,000USD7,937,000USD5,768,000USD5,004,000USD
    Cash And Equivalents2,626,000USD———————
    Total Current Assets3,174,000USD4,443,000USD5,387,000USD6,656,000USD4,839,000USD6,050,000USD4,169,000USD4,742,000USD
    Other Current Assets136,000USD768,000USD896,000USD1,081,000USD1,805,000USD2,434,000USD38,000USD10,000USD
    Total Liabilities265,000USD———————
    Total Current Liabilities265,000USD431,000USD199,000USD402,000USD676,000USD805,000USD992,000USD1,672,000USD
    Total Stockholder Equity4,191,000USD5,313,000USD6,341,000USD7,664,000USD5,997,000USD7,132,000USD4,776,000USD3,332,000USD
    Total Equity Including Noncontrolling Interest4,191,000USD———————
    Accounts Payable265,000USD431,000USD199,000USD—676,000USD805,000USD992,000USD1,530,000USD
    Common Stock21,000USD21,000USD21,000USD21,000USD18,000USD16,000USD—13,000USD
    Retained Earnings-17,304,000USD-15,916,000USD-14,262,000USD-12,897,000USD-11,499,000USD-10,077,000USD-8,815,000USD-7,835,000USD
    Intangible Assets—22,000USD62,000USD102,000USD142,000USD182,000USD222,000USD262,000USD
    Total Liab—431,000USD199,000USD402,000USD676,000USD805,000USD992,000USD1,672,000USD
    Other Current Liab—431,000USD199,000USD402,000USD—992,000USD——
    Capital Stock—21,000USD21,000USD21,000USD18,000USD500,000USD14,000USD13,000USD
    Cash—3,675,000USD4,491,000USD5,575,000USD3,034,000USD3,616,000USD1,272,000USD3,217,000USD
    Cash And Short Term Investments—3,675,000USD4,491,000USD5,575,000USD3,034,000USD3,616,000USD—3,217,000USD
    Net Debt—-3,675,000USD-4,491,000USD-5,575,000USD-3,034,000USD-3,616,000USD—-3,075,000USD
    Common Stock Shares Outstanding—21,010,132shares18,427,787shares20,206,033shares17,213,017shares15,875,485shares13,736,597shares10,910,227shares
    Non Current Assets Total—1,301,000USD1,153,000USD1,410,000USD1,834,000USD1,887,000USD1,599,000USD262,000USD
    Non Current Liabilities Total—0USD0USD0USD0USD447,999USD0USD0USD
    Non Currrent Assets Other—1,279,000USD1,091,000USD1,308,000USD1,692,000USD1,705,000USD——
    Net Working Capital—4,012,000USD5,188,000USD6,254,000USD4,163,000USD5,245,000USD3,177,000USD3,070,000USD
    Unclassified Equity—21,187,000USD20,561,000USD20,519,000USD17,460,000USD16,209,000USD13,577,000USD11,141,000USD
    Accumulated Other Comprehensive Income—————484,000USD——
    Unclassified Current Assets——————2,859,000USD—
    Unclassified Non Current Assets——————1,377,000USD—
    Short Term Debt———————142,000USD
    Short Long Term Debt———————142,000USD
    Short Long Term Debt Total———————142,000USD
    Net Receivables———————1,515,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USD
    Total Assets6,540,000USD6,216,000USD965,000USD1,036,000USD775,000USD14,308USD
    Intangible Assets62,000USD222,000USD382,000USD542,000USD702,000USD—
    Other Current Assets896,000USD2,896,999USD8,000USD———
    Total Liab199,000USD1,440,000USD3,043,000USD2,215,000USD1,942,000USD357,146USD
    Total Stockholder Equity6,341,000USD4,776,000USD-2,078,000USD-1,179,000USD-1,167,000USD-342,838USD
    Other Current Liab199,000USD992,000USD4,000USD4,000USD14,000USD—
    Common Stock21,000USD14,000USD11,000USD10,000USD10,000USD192,389USD
    Capital Stock21,000USD14,000USD11,000USD10,000USD10,000USD192,389USD
    Retained Earnings-14,262,000USD-8,815,000USD-6,212,000USD-4,400,000USD-3,350,000USD-1,204,838USD
    Cash4,491,000USD1,272,000USD93,000USD437,000USD73,000USD14,308USD
    Cash And Short Term Investments4,491,000USD1,272,000USD93,000USD437,000USD73,000USD14,308USD
    Total Current Assets5,387,000USD4,168,999USD101,000USD437,000USD73,000USD14,308USD
    Total Current Liabilities199,000USD992,000USD2,405,000USD1,633,000USD1,942,000USD357,146USD
    Net Debt-4,491,000USD-1,272,000USD545,000USD149,000USD307,000USD35,692USD
    Accounts Payable199,000USD992,000USD2,401,000USD1,629,000USD1,548,000USD307,146USD
    Common Stock Shares Outstanding18,427,787shares11,356,451shares10,382,515shares10,236,764shares12,841,937shares11,215,807shares
    Non Current Assets Total1,153,000USD2,047,000USD864,000USD599,000USD702,000USD0USD
    Non Current Liabilities Total0USD447,999USD638,000USD582,000USD0USD0USD
    Non Currrent Assets Other1,091,000USD1,377,000USD482,000USD57,000USD——
    Net Working Capital5,188,000USD3,177,000USD-1,490,000USD-1,196,000USD-1,869,000USD-342,838USD
    Unclassified Equity20,561,000USD13,563,000USD4,112,000USD3,201,000USD2,163,000USD—
    Short Term Debt——4,000USD4,000USD380,000USD50,000USD
    Short Long Term Debt Total——638,000USD586,000USD380,000USD50,000USD
    Long Term Debt——638,000USD582,000USD——
    Short Long Term Debt————380,000USD50,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation62,000USD
    Change In Working Capital-85,000USD
    Operating Cash Flow-2,048,000USD
    Financing Cash Flow183,000USD
    Change In Cash-1,865,000USD
    End Cash Flow2,626,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-1,654,000USD-1,365,000USD-1,398,000USD-1,422,000USD-1,262,000USD-980,000USD-1,046,999USD-253,000USD
    Depreciation40,000USD40,000USD40,000USD40,000USD40,000USD40,000USD40,000USD40,000USD
    Other Non Cash Items479,000USD471,000USD730,000USD1,375,000USD-253,000USD-471,000USD685,999USD19,000USD
    Change In Working Capital99,000USD-230,000USD-210,000USD-798,000USD432,000USD-610,000USD-1,699,000USD26,000USD
    Total Cash From Operating Activities-1,036,000USD-1,084,000USD-838,000USD-805,000USD-714,000USD-1,803,000USD-2,020,000USD-168,000USD
    Capital Expenditures0USD-838,000USD-838,000USD0USD0USD0USD0USD0USD
    Free Cash Flow-1,036,000USD-1,084,000USD-838,000USD-805,000USD-714,000USD-1,803,000USD-2,020,000USD-168,000USD
    Total Cash From Financing Activities220,000USD0USD3,379,000USD223,000USD3,058,000USD-142,000USD5,216,000USD149,000USD
    Issuance Of Capital Stock385,000USD0USD-223,000USD223,000USD0USD0USD5,524,000USD—
    Change In Cash-816,000USD-1,084,000USD2,541,000USD-582,000USD2,344,000USD-1,945,000USD3,196,000USD-19,000USD
    Begin Period Cash Flow4,491,000USD5,575,000USD3,034,000USD3,616,000USD1,272,000USD3,217,000USD21,000USD40,000USD
    End Period Cash Flow3,675,000USD4,491,000USD5,575,000USD3,034,000USD3,616,000USD1,272,000USD3,217,000USD21,000USD
    Other Cashflows From Financing Activities220,000USD6,660,000USD3,379,000USD223,000USD288,000USD—-390,000USD149,000USD
    Stock Based Compensation—-76,000USD-76,000USD—76,000USD———
    Net Borrowings—0USD0USD——-142,000USD40,000USD—
    Unclassified Financing Cash Flow—-6,660,000USD——2,770,000USD———
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USD
    Net Income-5,447,000USD-2,603,000USD-1,812,000USD-1,050,000USD-2,145,000USD-1,051,353USD
    Depreciation160,000USD160,000USD160,000USD160,000USD98,000USD0USD
    Other Non Cash Items2,652,000USD254,000USD56,000USD408,000USD144,000USD—
    Change In Working Capital-806,000USD-1,984,000USD764,000USD129,000USD1,191,000USD212,818USD
    Total Cash From Operating Activities-3,441,000USD-3,955,000USD81,000USD-353,000USD-412,000USD-38,535USD
    Capital Expenditures0USD0USD0USD0USD0USD-5USD
    Free Cash Flow-3,441,000USD-3,955,000USD81,000USD-353,000USD-412,000USD-38,535USD
    Net Borrowings0USD0USD0USD895,000USD330,000USD—
    Total Cash From Financing Activities6,660,000USD5,134,000USD-425,000USD717,000USD580,000USD37,000USD
    Issuance Of Capital Stock0USD5,524,000USD0USD0USD250,000USD0USD
    Change In Cash3,219,000USD1,179,000USD-344,000USD364,000USD59,000USD-1,535USD
    Begin Period Cash Flow1,272,000USD93,000USD437,000USD73,000USD14,000USD15,843USD
    End Period Cash Flow4,491,000USD1,272,000USD93,000USD437,000USD73,000USD14,308USD
    Other Cashflows From Financing Activities3,602,000USD-390,000USD-425,000USD-121,000USD—-13,000USD
    Unclassified Financing Cash Flow3,058,000USD—————
    Stock Based Compensation—218,000USD913,000USD0USD300,000USD800,000USD
    Investments———0USD-109,000USD0USD
    Total Cashflows From Investing Activities————-109,000USD—
    Other Cashflows From Investing Activities————-109,000USD—
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    No revenue breakdown is currently published for this company.

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.